BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 28368997)

  • 21. Effect of timolol, latanoprost, and dorzolamide on circadian IOP in glaucoma or ocular hypertension.
    Orzalesi N; Rossetti L; Invernizzi T; Bottoli A; Autelitano A
    Invest Ophthalmol Vis Sci; 2000 Aug; 41(9):2566-73. PubMed ID: 10937568
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Geographic and Provider Variations in Ocular Hypotensive Medication Claims Among Medicare Part D Enrollees.
    Janetos TM; French DD; Beaumont JL; Tanna AP
    J Glaucoma; 2019 Feb; 28(2):e29-e33. PubMed ID: 30358645
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Brimonidine tartrate 0.15%, dorzolamide hydrochloride 2%, and brinzolamide 1% compared as adjunctive therapy to prostaglandin analogs.
    Bournias TE; Lai J
    Ophthalmology; 2009 Sep; 116(9):1719-24. PubMed ID: 19592108
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Glaucoma severity and medication adherence in a county hospital population.
    Ung C; Zhang E; Alfaro T; Murakami Y; Zhang M; Seider MI; Lin SC; Singh K
    Ophthalmology; 2013 Jun; 120(6):1150-7. PubMed ID: 23453512
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Use of electronic patient data overview with alerts in primary care increases prescribing of lipid-lowering medications in patients with type 2 diabetes.
    Charles MH; Thomsen JL; Christensen B; Pulleyblank R; Kongstad LP; Olsen KR
    Diabetologia; 2022 Feb; 65(2):286-290. PubMed ID: 34709425
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Additive intraocular pressure reduction effect of fixed combination of maleate timolol 0.5%/dorzolamide 2% (Cosopt) on monotherapy with latanoprost (Xalatan) in patients with elevated intraocular pressure: a prospective, 4-week, open-label, randomized, controlled clinical trial.
    Hatanaka M; Reis A; Sano ME; Susanna R
    J Glaucoma; 2010; 19(5):331-5. PubMed ID: 19730119
    [TBL] [Abstract][Full Text] [Related]  

  • 27. 24-hour efficacy of the bimatoprost-timolol fixed combination versus latanoprost as first choice therapy in subjects with high-pressure exfoliation syndrome and glaucoma.
    Konstas AG; Holló G; Mikropoulos DG; Haidich AB; Dimopoulos AT; Empeslidis T; Teus MA; Ritch R
    Br J Ophthalmol; 2013 Jul; 97(7):857-61. PubMed ID: 23686322
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intraocular pressure response to medication in a clinical setting: the Marshfield Clinic Personalized Medicine Research Project.
    McCarty CA; Mukesh BN; Kitchner TE; Hubbard WC; Wilke RA; Burmester JK; Patchett RB
    J Glaucoma; 2008 Aug; 17(5):372-7. PubMed ID: 18703947
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effectiveness and safety of dorzolamide-timolol alone or combined with latanoprost in open-angle glaucoma or ocular hypertension.
    Lesk MR; Koulis T; Sampalis F; Sampalis JS; Bastien NR
    Ann Pharmacother; 2008 Apr; 42(4):498-504. PubMed ID: 18364402
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Measurement of persistence and adherence to regimens of IOP-lowering glaucoma medications using pharmacy claims data.
    Wilensky J; Fiscella RG; Carlson AM; Morris LS; Walt J
    Am J Ophthalmol; 2006 Jan; 141(1 Suppl):S28-33. PubMed ID: 16389058
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Twice-daily 0.2% brimonidine-0.5% timolol fixed-combination therapy vs monotherapy with timolol or brimonidine in patients with glaucoma or ocular hypertension: a 12-month randomized trial.
    Sherwood MB; Craven ER; Chou C; DuBiner HB; Batoosingh AL; Schiffman RM; Whitcup SM
    Arch Ophthalmol; 2006 Sep; 124(9):1230-8. PubMed ID: 16966616
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Meta-analysis of 24-hour intraocular pressure studies evaluating the efficacy of glaucoma medicines.
    Stewart WC; Konstas AG; Nelson LA; Kruft B
    Ophthalmology; 2008 Jul; 115(7):1117-1122.e1. PubMed ID: 18082886
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of the nocturnal effects of once-daily timolol and latanoprost on intraocular pressure.
    Liu JH; Kripke DF; Weinreb RN
    Am J Ophthalmol; 2004 Sep; 138(3):389-95. PubMed ID: 15364220
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Drug utilization among hypertensive patients in the outpatient department of medicine in a tertiary care hospital: A cross-sectional study.
    Paradkar SG; Sinha SR
    Clin Exp Hypertens; 2018; 40(2):150-154. PubMed ID: 28816547
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Availability, cost, and prescription patterns of antihypertensive medications in primary health care in China: a nationwide cross-sectional survey.
    Su M; Zhang Q; Bai X; Wu C; Li Y; Mossialos E; Mensah GA; Masoudi FA; Lu J; Li X; Salas-Vega S; Zhang A; Lu Y; Nasir K; Krumholz HM; Jiang L
    Lancet; 2017 Dec; 390(10112):2559-2568. PubMed ID: 29102087
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Central corneal thickness and measured IOP response to topical ocular hypotensive medication in the Ocular Hypertension Treatment Study.
    Brandt JD; Beiser JA; Gordon MO; Kass MA;
    Am J Ophthalmol; 2004 Nov; 138(5):717-22. PubMed ID: 15531304
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A comparison of the effects of dorzolamide/timolol fixed combination versus latanoprost on intraocular pressure and pulsatile ocular blood flow in primary open-angle glaucoma patients.
    Janulevicienë I; Harris A; Kagemann L; Siesky B; McCranor L
    Acta Ophthalmol Scand; 2004 Dec; 82(6):730-7. PubMed ID: 15606472
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A 6-week, double-masked, parallel-group study of the efficacy and safety of travoprost 0.004% compared with latanoprost 0:005%/timolol 0.5% in patients with primary open-angle glaucoma or ocular hypertension.
    Franks WA; Renard JP; Cunliffe IA; Rojanapongpun P
    Clin Ther; 2006 Mar; 28(3):332-9. PubMed ID: 16750448
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Randomized trial of brinzolamide/brimonidine versus brinzolamide plus brimonidine for open-angle glaucoma or ocular hypertension.
    Gandolfi SA; Lim J; Sanseau AC; Parra Restrepo JC; Hamacher T
    Adv Ther; 2014 Dec; 31(12):1213-27. PubMed ID: 25430900
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Latanoprost versus timolol as first choice therapy in patients with ocular hypertension. A cost-effectiveness analysis.
    Peeters A; Schouten JS; Severens JL; Hendrikse F; Prins MH; Webers CA
    Acta Ophthalmol; 2012 Mar; 90(2):146-54. PubMed ID: 20731623
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.